PL3113774T3 - Kompozycje grapiprantu i sposoby ich zastosowania - Google Patents

Kompozycje grapiprantu i sposoby ich zastosowania

Info

Publication number: PL3113774T3
Authority: PL; Poland
Prior art keywords: grapiprant; compositions; methods; same
Prior art date: 2014-03-06

Application number

PL15758877T

Other languages

English (en)

Inventor

Lesley Rausch-Derra

Tamara NEWBOLD

Gopinath DEVARAJ

Akemi Shiraishi

Original Assignee

Elanco Animal Health Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-06

Filing date

2015-03-05

Publication date

2022-06-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54016294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3113774(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-05 Application filed by Elanco Animal Health Incorporated filed Critical Elanco Animal Health Incorporated

2022-06-13 Publication of PL3113774T3 publication Critical patent/PL3113774T3/pl

Links

HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical group CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 title 1
229950004517 grapiprant Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL15758877T 2014-03-06 2015-03-05 Kompozycje grapiprantu i sposoby ich zastosowania PL3113774T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201461948957P	2014-03-06	2014-03-06
US201462089713P	2014-12-09	2014-12-09
PCT/US2015/019037 WO2015134792A1 (en)	2014-03-06	2015-03-05	Compositions of grapiprant and methods for using the same
EP15758877.3A EP3113774B1 (en)	2014-03-06	2015-03-05	Compositions of grapiprant and methods for using the same

Publications (1)

Publication Number	Publication Date
PL3113774T3 true PL3113774T3 (pl)	2022-06-13

Family

ID=54016294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15758877T PL3113774T3 (pl)	2014-03-06	2015-03-05	Kompozycje grapiprantu i sposoby ich zastosowania

Country Status (15)

Country	Link
US (4)	US11369621B2 (pl)
EP (1)	EP3113774B1 (pl)
JP (1)	JP6419857B2 (pl)
KR (1)	KR102270323B1 (pl)
CN (2)	CN112370450A (pl)
AU (1)	AU2015227059B2 (pl)
CA (1)	CA2941008C (pl)
DK (1)	DK3113774T3 (pl)
ES (1)	ES2907285T3 (pl)
MX (3)	MX376175B (pl)
PL (1)	PL3113774T3 (pl)
PT (1)	PT3113774T (pl)
RU (1)	RU2679631C2 (pl)
TW (2)	TWI664969B (pl)
WO (1)	WO2015134792A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3113774T (pt) *	2014-03-06	2022-02-28	Elanco Animal Health Incorporated	Composições de grapiprant e métodos de utilização das mesmas
US12109218B2 (en) *	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
US20210315909A1 (en) *	2018-07-11	2021-10-14	Arrys Therapeutics, Inc.	Polymorphic compounds and uses thereof
EP3856177A4 (en) *	2018-09-27	2022-06-29	Arrys Therapeutics, Inc.	Grapiprant unit dosage forms
CN115697317A (zh) *	2020-04-08	2023-02-03	株式会社AskAt	Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DZ2479A1 (fr)	1997-05-05	2003-02-01	Pfizer	Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
AU6836200A (en) *	1999-08-10	2001-03-05	Glaxo Group Limited	Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
HN2001000224A (es)	2000-10-19	2002-06-13	Pfizer	Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
WO2003008637A2 (en)	2001-07-17	2003-01-30	Xanthus Life Sciences, Inc.	Use of genotyping in the individualization of therapy
JP2005511562A (ja) *	2001-10-31	2005-04-28	メディカルリサーチカウンシル	月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
CN100579518C (zh)	2002-04-12	2010-01-13	美国辉瑞有限公司	Ep4受体配体在制备治疗il-6相关疾病的药物中的应用
WO2005102389A2 (en) *	2004-04-20	2005-11-03	Pfizer Products Inc.	Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
CA2600510C (en)	2005-03-11	2010-11-02	Pfizer Inc.	Crystal forms of an imidazole derivative
ES2392192T3 (es) *	2006-04-24	2012-12-05	Merck Canada Inc.	Derivados de indol amida como antagonistas del receptor EP4
US20080242713A1 (en) *	2007-03-28	2008-10-02	Bayer Schering Pharma Aktiengesellschaft	Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
US9457084B2 (en)	2010-02-22	2016-10-04	Raqualia Pharma Inc.	Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases
EP2555774B1 (de) *	2010-04-08	2015-10-21	Boehringer Ingelheim International GmbH	Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
WO2012048854A2 (en) *	2010-10-12	2012-04-19	Merz Pharma Gmbh & Co. Kgaa	Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US8591944B2 (en)	2011-03-08	2013-11-26	Zalicus Pharmaceuticals Ltd.	Solid dispersion formulations and methods of use thereof
WO2012157288A1 (en)	2011-05-18	2012-11-22	Raqualia Pharma Inc.	Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
ITBO20110461A1 (it) *	2011-07-29	2013-01-30	Alfa Wassermann Spa	Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2907049C (en)	2013-03-19	2021-08-10	Askat Inc.	Use of ep4 receptor antagonists in the treatment of cartilage disease
US12109218B2 (en) *	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
CN107759590A (zh)	2014-03-06	2018-03-06	阿莱塔纳治疗学股份有限公司	Grapiprant的结晶形式
PT3113774T (pt) *	2014-03-06	2022-02-28	Elanco Animal Health Incorporated	Composições de grapiprant e métodos de utilização das mesmas

2015
- 2015-03-05 PT PT157588773T patent/PT3113774T/pt unknown
- 2015-03-05 RU RU2016137926A patent/RU2679631C2/ru active
- 2015-03-05 CA CA2941008A patent/CA2941008C/en active Active
- 2015-03-05 TW TW104107084A patent/TWI664969B/zh active
- 2015-03-05 JP JP2016573691A patent/JP6419857B2/ja active Active
- 2015-03-05 DK DK15758877.3T patent/DK3113774T3/da active
- 2015-03-05 TW TW106126404A patent/TWI708606B/zh active
- 2015-03-05 PL PL15758877T patent/PL3113774T3/pl unknown
- 2015-03-05 US US14/639,898 patent/US11369621B2/en active Active
- 2015-03-05 CN CN202011270789.4A patent/CN112370450A/zh active Pending
- 2015-03-05 ES ES15758877T patent/ES2907285T3/es active Active
- 2015-03-05 WO PCT/US2015/019037 patent/WO2015134792A1/en not_active Ceased
- 2015-03-05 EP EP15758877.3A patent/EP3113774B1/en active Active
- 2015-03-05 MX MX2016011025A patent/MX376175B/es active IP Right Grant
- 2015-03-05 KR KR1020167027433A patent/KR102270323B1/ko active Active
- 2015-03-05 CN CN201580006168.6A patent/CN105939713A/zh active Pending
- 2015-03-05 AU AU2015227059A patent/AU2015227059B2/en active Active
2016
- 2016-05-02 US US15/144,609 patent/US20160317559A1/en not_active Abandoned
- 2016-08-24 MX MX2020001428A patent/MX2020001428A/es unknown
- 2016-08-24 MX MX2022014763A patent/MX2022014763A/es unknown
2024
- 2024-10-07 US US18/908,587 patent/US12478633B2/en active Active
2025
- 2025-10-30 US US19/374,274 patent/US20260053822A1/en active Pending

Also Published As

Publication number	Publication date
RU2019102384A3 (pl)	2022-03-31
MX2016011025A (es)	2016-11-29
US20150250773A1 (en)	2015-09-10
RU2679631C2 (ru)	2019-02-12
TWI664969B (zh)	2019-07-11
US12478633B2 (en)	2025-11-25
EP3113774B1 (en)	2022-01-26
JP6419857B2 (ja)	2018-11-07
DK3113774T3 (da)	2022-03-07
EP3113774A1 (en)	2017-01-11
JP2017507190A (ja)	2017-03-16
MX2020001428A (es)	2020-03-20
NZ761827A (en)	2021-03-26
US20250025481A1 (en)	2025-01-23
RU2019102384A (ru)	2019-03-04
TW201815393A (zh)	2018-05-01
US20260053822A1 (en)	2026-02-26
MX2022014763A (es)	2023-01-11
US20160317559A1 (en)	2016-11-03
TWI708606B (zh)	2020-11-01
CN112370450A (zh)	2021-02-19
US11369621B2 (en)	2022-06-28
ES2907285T3 (es)	2022-04-22
NZ724007A (en)	2021-02-26
WO2015134792A1 (en)	2015-09-11
EP3113774A4 (en)	2017-10-25
TW201603812A (zh)	2016-02-01
CA2941008A1 (en)	2015-09-11
RU2016137926A (ru)	2018-04-09
PT3113774T (pt)	2022-02-28
KR20160129887A (ko)	2016-11-09
CA2941008C (en)	2022-07-26
CN105939713A (zh)	2016-09-14
AU2015227059B2 (en)	2018-11-15
MX376175B (es)	2025-03-07
KR102270323B1 (ko)	2021-06-29
AU2015227059A1 (en)	2016-09-22

Publication	Publication Date	Title
ZA201701244B (en)	2018-05-30	Carrier-antibody compositions and methods of making and using the same
GB2535253B (en)	2019-04-17	Compositions and methods
GB2546350B (en)	2019-12-04	Compositions and methods
SG10202109655VA (en)	2021-10-28	Compositions and methods for immunooncology
GB2535423B (en)	2021-06-23	Cementing compositions and methods
HUE056172T2 (hu)	2022-01-28	Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
IL246879A0 (en)	2016-08-31	Preparations of Epilimod and methods of using them
GB201718876D0 (en)	2017-12-27	Antithrombin-heparin compositions and methods
ZA202104969B (en)	2023-01-25	Compositions comprising 15-hepe and methods of using the same
GB201417828D0 (en)	2014-11-19	New methods and compositions
EP3166892A4 (en)	2018-03-14	Scale-inhibition compositions and methods of making and using the same
PT3113774T (pt)	2022-02-28	Composições de grapiprant e métodos de utilização das mesmas
GB201715820D0 (en)	2017-11-15	Compositions and methods
GB201705626D0 (en)	2017-05-24	Compositions and methods
ZA201807665B (en)	2020-02-26	Methods and compositions
ZA201606594B (en)	2018-11-28	Defoamer compositions and methods of using the same
EP3207029A4 (en)	2018-05-02	Tryptamide compositions and methods of use
GB201512996D0 (en)	2015-09-09	Compositions and methods
EP3221366A4 (en)	2018-05-23	Polyaminomethylbenzyloxalamides and compositions and methods related thereto
GB201514413D0 (en)	2015-09-30	Compositions and methods
GB201402915D0 (en)	2014-04-02	Compositions and methods
ZA201807782B (en)	2020-05-27	Methods and compositions
IL256261B (en)	2022-06-01	Hide1 compositions and methods
GB201403212D0 (en)	2014-04-09	Compositions and methods
GB201522554D0 (en)	2016-02-03	Methods and compositions